Viridian Therapeutics, Inc. (NASDAQ: VRDN) secures a spot on the list of the best small-cap biotech stocks to buy according to analysts with significant upside potential. RBC Capital raised its price target on VRDN from $41 to $45, maintaining an “Outperform” rating, citing clear profitability visibility and a cash position of $888 million.

The investment firm’s bullish stance on Viridian Therapeutics, Inc. (NASDAQ: VRDN) is driven by completed key patient enrollments in late-stage clinical studies, with readouts for active and chronic Thyroid Eye Disease (TED) expected in Q1 and Q2 2026. The company reported Q3 2025 results, closing the quarter with $490.9 million in cash on hand.

Focused on developing and commercializing therapies for rare diseases, Viridian Therapeutics, Inc. (NASDAQ: VRDN) saw a significant increase in R&D expenses in Q3 2025, growing from $69.2 million to $86.3 million. While acknowledged as a potential investment, certain AI stocks offer greater upside potential with less downside risk, according to analysts.

For investors seeking undervalued AI stocks, an alternative to VRDN, see the free report on the best short-term AI stock. Explore the 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential for more investment opportunities. No disclosure of holdings mentioned in the article.

Read more at Yahoo Finance: RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results